Article
Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
Pharmacogenomics - 1 May 2017
Taranu Adela, Colle Romain, Gressier Florence, El Asmar Khalil, Becquemont Laurent, Corruble Emmanuelle, Verstuyft Céline
Abstract excerpt
AIM: The antidepressant venlafaxine (VEN) is metabolized by CYP2D6 and CYP2C19. The aim of this study was to assess the relevance of generalizing to daily practice the genotyping of CYP2D6 and CYP2C19 to predict VEN efficacy in depressed patients treated in psychiatric settings. PATIENTS & METHODS: This study was nested in a naturalistic cohort, with 206 patients requiring a new antidepressant treatment and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.